Research & Publications

Translational research has always been the linchpin of Lifedoc’s clinical framework, further enabling us to provide healthcare that is quality-oriented and data-driven. Over the last 15 years, research has remained an integral part of our efforts to maximize the applicability of health data. With active participation in industry-sponsored and investigator-initiated research, we aim to to inform emerging treatments and continually refine our clinical model for the ultimate benefit of the patient. This focus allows us to continually develop data to support our evidence-based approach, ensuring that our patients receive the most effective healthcare and clinical interventions. Ultimately, this allows us to fulfill our mission of establishing Lifedoc as a reference model for researchers and practitioners studying the development and prevention of cardiometabolic conditions.

Take a look at our past and ongoing trials, research partnerships as well as some of our published/presented studies below.

Interested in working with our research site? Contact us.

Quality care for all. A kid playing doctor.

Research Partnerships

Novo Nordisk

Industry-sponsored Clinical Trials

Ongoing Trials

– Boehringer-Ingleheim – Safety and Efficacy of SGLT-2 and DPP-4 in Type 2 Diabetes, Children 10 – 17 years of age.

Past Trials

– Janssen – Safety and Efficacy of SGLT-2  in Type 2 Diabetes, Adults – Recognized as Highest Recruiting/Retaining Site in the US

– Novo Nordisk – Safety and Efficacy of Liraglutide in Overweight and Obesity, Children and Adolescents 10-17 years of age – Recruited First and Second Patient Globally

–  Novo Nordisk – Safety and Efficacy of Liraglutide and Metformin in Type 2 Diabetes, Children and Adolescents 10-17 years of age – Recognized as Highest Recruiting Site in the US

Notable Publications

Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects

Published: International journal of obesity and related metabolic disorders
Date:
Authors: P A Velasquez-Mieyer 1 , P A Cowan, G E Umpierrez, R H Lustig, A K Cashion, G A Burghen
Abstract:
Obese African-American (AA) subjects have higher resting and stimulated insulin concentrations than obese Caucasians (C), which could not be explained by the severity of obesity or the degree of insulin sensitivity. We investigated whether differences in glucagon-like peptide-1 (GLP-1), the most potent incretin that regulates insulin secretion, might explain racial differences in insulin response.

Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults

Published: International journal of obesity and related metabolic disorders
Date:
Authors: P A Velasquez-Mieyer 1 , P A Cowan, K L Arheart, C K Buffington, K A Spencer, B E Connelly, G W Cowan, R H Lustig
Abstract:
Hyperinsulinemia is a common feature of many obesity syndromes. We investigated whether suppression of insulin secretion, without dietary or exercise intervention, could promote weight loss and alter food intake and preference in obese adults.

Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist

Published: The Journal of Pediatrics
Date:
Authors: R H Lustig 1 , S R Rose, G A Burghen, P Velasquez-Mieyer, D C Broome, K Smith, H Li, M M Hudson, R L Heideman, L E Kun
Abstract:
Hypothalamic obesity is a rare sequela of cranial insult, for which pathogenesis and treatment remain obscure. In rodents ventromedial hypothalamic damage causes hyperphagia, obesity, hyperinsulinism, and insulin resistance. Reduction of insulin secretion in humans may attenuate weight gain.
1 … 10 11 12

Contact Us